Academic Journal
Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis
| العنوان: | Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis |
|---|---|
| المساهمون: | College of Medicine, Dept. of Pediatrics, Andreas Kronbichler, Johannes Leierer, Jun Oh, Bj철rn Meijers, Jae Il Shin, Shin, Jae Il |
| بيانات النشر: | Hindawi Pub. Co. United States |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Disease Progression, Glomerulosclerosis, Focal Segmental/drug therapy, Focal Segmental/immunology, Focal Segmental/pathology, Humans, Immunosuppressive Agents/therapeutic use, Interleukin-1beta/immunology, Kidney Failure, Chronic/drug therapy, Chronic/immunology, Chronic/pathology, Kidney Glomerulus/immunology, Kidney Glomerulus/pathology, Kidney Transplantation/adverse effects, Transforming Growth Factor beta1/immunology, Tumor Necrosis Factor-alpha/immunology |
| الوصف: | Focal segmental glomerulosclerosis is a histological pattern on renal biopsy caused by diverse mechanisms. In its primary form, a circulatory factor is implicated in disease onset and recurrence. The natural history of primary FSGS is unpredictable, since some patients are unresponsive towards immunosuppressive measures. Immunologic changes, leading to a proinflammatory or profibrotic milieu, have been implicated in disease progression, namely, glomerular scarring, eventually leading to end-stage renal disease. Among these, interleukin-1횩, tumor-necrosis factor-慣 (TNF-慣), and transforming growth factor-횩1 (TGF-횩1) have emerged as important factors. Translating these findings into clinical practice dampened the enthusiasm, since both TNF-慣 and TGF-횩1 blockade failed to achieve significant control of the disease. More recently, a role of the complement system has been demonstrated which in fact may be another attractive target in clinical practice. Rituximab, blocking CD20-bearing cells, demonstrated conflicting data regarding efficacy in FSGS. Finally, the T-cell costimulating molecule B7-1 (CD80) is implicated in development of proteinuria in general. Blockade of this target demonstrated significant benefits in a small cohort of resistant patients. Taken together, this review focuses on immunology of FSGS, attributable to either the disease or progression, and discusses novel therapeutic approaches aiming at targeting immunologic factors. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| تدمد: | 2314-6133 2314-6141 |
| Relation: | BIOMED RESEARCH INTERNATIONAL; J00315; 2012~; ~2012 Journal of Biomedicine & Biotechnology; OAK-2016-01216; https://ir.ymlib.yonsei.ac.kr/handle/22282913/146519; T201600796; BIOMED RESEARCH INTERNATIONAL, Vol.2016 : 2150451, 2016 |
| DOI: | 10.1155/2016/2150451 |
| الاتاحة: | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146519 https://doi.org/10.1155/2016/2150451 |
| Rights: | CC BY-NC-ND 2.0 KR ; https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ |
| رقم الانضمام: | edsbas.4E729F3A |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 23146133 23146141 |
|---|---|
| DOI: | 10.1155/2016/2150451 |